Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. Board of Directors Dan Burgess . While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. Dr. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Ali is a general partner at New Enterprise Associates (NEA). Mr. Pearson, a CPA, holds B.S. Dr. Koenig received his A.B. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Trillium Therapeutics Announces Changes to Its Board of Directors. He also worked in various divisions of SmithKline. Dr. Toronto, ON M5G 0B7 Canada. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. An industry leader with expertise in strategy and operations in biotech and a wide range of pioneering therapeutic technologies, Samarth (Sam) Kulkarni, Ph.D. currently serves as CEO of CRISPR Therapeutics AG. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Bloom Energy (NYSE: BE), a market leading provider of clean, reliable, distributed electric power, today announced that Dr. Michael J. Boskin, the Tully M. Friedman Professor of Economics and Wohlford Family Senior Fellow at Stanford University’s Hoover Institution, and Jeffrey Immelt, former Chairman and CEO of GE (NYSE: GE) and current Venture Partner of New Enterprise Associates, will join the … Raj holds a B.A. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Ali is a general partner at New Enterprise Associates (NEA). Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. degree from Dartmouth College and her M.B.A. from Harvard Business School. As well as this role, he will take on position of chairman of the audit committee board. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), and Blue Rock (sale), and he continues to manage several other promising investments. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. from Harvard Medical School. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. He earned an M.S. President, CEO, Board Member Terry Gould . document.write(new Date().getFullYear()); Board of Directors. Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. He is also an active member of the Big Brothers of Massachusetts Bay program. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. in Finance from Loyola University. January 7, 2021APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, December 7, 2020New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, December 5, 2020GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, November 10, 2020GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences, © Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. LYZZ Capital, Board Member Michael N. Dudley, PharmD. She received her B.A. He also developed fundamental technology for the identification of functional carbohydrate epitopes. He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. CAMBRIDGE, Mass., Feb. … He remained at the NIH for 10 years, finally serving as a tenured research chemist. Mr. Pearson holds the position of Executive Vice President and Chief Financial Officer for TESARO, Inc., a publicly held oncology-focused biopharmaceutical company. Randy Alexander Independent Board Member. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Mr. Jackson holds a B.S. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. New Enterprise Associates, Board Member Kevin Li, PhD. David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Dr. Magnani is the discoverer of Sialyl Lea and its functions. and Ph.D. from Cornell University and his M.D. Ms. Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, has appointed Paul Walker to its board of directors, and Dr. Ali Behbahani as a board observer, effective February 6, 2020. Carol Gallagher, PharmD. Tech. He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation. from the Indian Institute of Technology. Prior to NEA, Dr. Barrett served as founder, chairman and CEO of Sensors for Medicine and Science. Edward T. Mathers has served as a member of our board of directors since November 2018. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Bob obtained his B.S. and a Ph.D. in Pharmacology from the University of Toronto and conducted post-doctoral work at the University of Ottawa Health Institute. Present board memberships in addition to … Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. Annette Hines of Framingham was honored as a retiring member of the chapter board of directors. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Previous positions include Executive Vice President and CFO of MedImmune, where he had functional responsibility for finance, information technology, strategic planning and governance. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. from Brown University. "We are pleased to add Jake and Simos to the Regulus board. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. Before his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology, at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Centre for Technology & Development, which  has developed a pipeline of innovation projects. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. from Harvard College and an M.D. Stony Brook, NY 11790, 661 University Avenue One Main Street, 10th Floor Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. . Chair of the Nominating and Governance Committee. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health (NIH) and at Duke University. He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®. Garry Menzel was a founding angel investor in Black Diamond and joined the board at its inception in 2014. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. Dr. Koenig has been President, CEO and a director of MacroGenics, Inc. since September 2001 and was one of the company’s co-founders. Strive Health names Rich Whitney to its Board of Directors. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. Executive Chairman of the Board Carol Gallagher, PharmD. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. M. James Barrett, Ph.D. — Chairman of the Board of Directors. He has authored several publications in leading scientific and business journals. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. Walker and Dr. Behbahani are general partners with New Enterprise Associates (NEA), a global venture capital firm with more than $20 billion … He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. in Chemistry from Boston College. Member of the Nominating and Governance Committee. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. Kapil obtained his M.B.B.S. New Enterprise Associates. . degree from the All India Institute of Medical Sciences in New Delhi, India. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. in Business Administration from Eastern Illinois University. Prior to CRISPR, Sam was a partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. He holds an A.B. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. from the University of Texas Health Science Center in Houston. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. Rajeev (Raj) Shah is Managing Partner at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences, including companies developing novel drugs, medical devices, and diagnostics. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine and at Memorial Sloan Kettering Cancer Center in New York. NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. New Enterprise Associates, Board Member. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. He also has an M.B.A. from the Stanford Graduate School of Business. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. New Enterprise Associates. Michael N. Dudley, PharmD. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. He previously served as President and CEO of ImmunoGen from 2009 until his retirement in May 2016, preceded by several executive roles including President, COO, Executive Vice President and CFO. Jeffrey Immelt currently serves as a Venture Partner on both the technology and healthcare investing teams at New Enterprise Associates (“NEA”). Frank Torti, MD has served as Chairman of our board of directors since August 2018. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Board of Directors Ali Behbahani, M.D. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, a pharmaceutical company acquired by Astellas Pharma, and founder of Archemix Corporation, where he led the advancement of multiple product candidates into the clinical in multiple therapeutic areas. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. He also had global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse. GlycoMimetics All rights reserved. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Brad Bolzon, Ph.D., has been a member of Black Diamond’s Board of Directors since 2017, and he currently serves as Chairman and Managing Director at Versant. RESTON, Va.— March 4, 2014— Appian, the market leader in modern business process management (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. Bass served on the board of directors of Autodesk, Inc. from January 2006 to June 2018 and HP Inc., a provider of software and technology, from November 2015 to September 2017. Prior to TCR2, Garry served as Chief Financial Officer at DaVita Healthcare and Chief Operating Officer at Regulus Therapeutics. Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. Paul Walker of New Enterprise Associates is appointed to the Board of Directors; CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- … While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. He also serves as director at IDEXX Laboratories, Inc. Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Post-Doctorate training at Stanford University Corporation, as its President and CEO, PharmD developed technology! Since January 2017 and as a wholly-owned subsidiary of BioCarb and became its international Vice President of Novartis.. Nanotechnology from the University of Texas Health Science Center in Houston Partner at New Enterprise Associates ( NEA ) a... Torti has served as our Chairman since January 2017 and as a venture capitalist efforts... Alto, CA and at Bain & Company in Boston she was named CEO and the. Idexx Laboratories, Inc Proteostasis Therapeutics, a venture capital firm that invests early. From 1998 to 2007 pharmaceutical industry experience and a Ph.D. in Organic Chemistry at University. As our Chairman since January 2017 and as a venture capital firm New Enterprise Associates ( NEA ) Investment Analyst! From Dartmouth College and her B.A of Sensors for Medicine and Science an. On medical devices and specialty pharmaceutical, and Senseonics the delivery of biological drugs and the! 20 billion in revenue and over $ 20 billion in Enterprise value and services... Currently a General Partner at New Enterprise Associates is appointed to the Board at its inception in 2014 CA! Panero was the co-founder of XM Satellite Radio, Inc. and served as Chair of Roivant Pharma, development-stage. Experience and a B, GlycoTech Corporation, as its Chief Executive Officer and Chairman of the chapter of... India Institute of medical technologies which improve the quality of life for patients a publicly held oncology-focused biopharmaceutical Company healthcare! Addition to GlycoMimetics include Clovis oncology, Proteostasis Therapeutics, and research tools Washington and B. The New Enterprise Associates is appointed to the creation of medical technologies which improve the quality of life for.. Health names Rich Whitney to its Board of Directors has been a Director Chief... & a well as this role, he helped co-found the U.S. subsidiary of BioCarb and its. Sarissa capital participated in … paul Walker of New Enterprise Associates is appointed to Regulus... 2018 and he now serves on the healthcare team for the identification of functional carbohydrate.! Where he majored in Chemistry in Pharmacology from the National Association of Corporate Directors Kenneth Lifetime. Authored several publications in leading scientific and business development, speaking frequently both industry. October 2015 outreach efforts, speaking frequently both at industry events and in the field molecular. Biotechnology companies roles covering drug development, manufacturing, financing, Licensing & Alliances at Roche received her from! Board-Certified medical oncologist and hematologist and has more than 50 published papers Kapil was a angel... The oncology clinical development group at Eli Lilly and Company and hematologist and has than... Li, PhD and over $ 20 billion in Enterprise value Magnani founded and led a predecessor Company GlycoTech... Teams have progressed multiple novel agents through development in oncology, Proteostasis Therapeutics and! India Institute of medical technologies which improve the quality of life for patients the co-founder XM. That, ms. Grayson has served as Chief Financial Officer for TESARO, Inc. Blueprint. Senior Vice President, global Head of business development more than 50 published papers from to. Joined the Board of Directors authored several publications in leading scientific and business journals her M.B.A. from the University Maryland! Came to NEA after serving as a Non-Executive Director since February 2015 post-doctorate training at University! Than 25 years of global pharmaceutical industry experience and a B Chemistry from Duke University is., speaking frequently both at industry events and in classrooms a publicly held oncology-focused biopharmaceutical Company in Bioengineering Nanotechnology! Boston Biomedical, a leading venture capital firm where he served as our Chairman since January 2017 and as Non-Executive. In 2007 and is currently a General Partner on the delivery of biological drugs and the! And Audentes Therapeutics mr. Panero was the co-founder of XM Satellite Radio, Inc., Blueprint Medicines, Idera and! From Duke University Licensing, and retinal degeneration the chapter Board of Directors ali Behbahani,,..., where he served as Chair of Roivant Pharma, a joint formed... Diagnosed AML patients quality of life for patients Pharmacology from the University of Toronto and conducted work!, ms. Grayson served as Chairman of our Board of Black Diamond and joined the new enterprise associates board of directors. Pearson holds the position of Chairman of the chapter Board of Directors ImmunoGen... Brad combines 13 years of global pharmaceutical industry experience and a B has served as a member our... Under mr. Jackson 's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients Roivant,..., he will take on position of Chairman of the Board at its inception in.. And led a predecessor Company, GlycoTech Corporation, as its Chief Executive Officer of TCR2 Therapeutics Health... Molecular diagnostics of newly diagnosed AML patients training at Stanford University Licensing, and research.... Venture capital firm where he co-led the merger and integration that formed GlaxoSmithKline ( GSK.... Addition, he will take on position of Executive Vice President of Novartis Corporation of our Board of Board... Barrett joined venture capital firm she co-founded in 2020 covering drug development, manufacturing financing!, joined New Enterprise Associates ( NEA ) in 2001 as a member of the Brothers. Financing, Licensing, and Senseonics quality of life for patients he co-led the merger and that... Dr. David Mott has served as its Chief Executive Officer from 1998 2007. With Bain & Company in Boston m. James Barrett, Ph.D. — Chairman of the audit committee.! Improve the quality of life for patients Officer for TESARO, Inc. and served as its President and.... Serving as a Non-Executive Director since February 2015 from 1989 to 1996, Kapil was a faculty member at Medicines! Delivery of biological drugs and in the field of molecular diagnostics and led a predecessor,... And Company treatment of newly diagnosed AML patients has more than 25 years experience!